2024 ACoP——Abbisko will present the model-informed dose selection results for Pimicotinib (ABSK021)

On October 17, 2024, Abbisko Therapeutics (HKEX code: 02256) announced that the company will present a model-informed dose selection study of pimicotinib in the treatment of tenosynovial giant cell tumor (TGCT) at the 2024 American Conference on Pharmacometrics (ACoP). The ACoP conference will be held in Phoenix, USA from November 10 to 13. Abbisko presentation at ACoP 2024: Abstract Number: M-082 Title: Integration of pharmacokinetics, safety, and efficacy into model-informed dose selection for pimicotinib Poster Time: 11 Nov, 2024 About Pimicotinib Pimicotinib is a novel, orally available, highly selective, and highly potent small molecule inhibitor of CSF-1R independently discovered and developed by Abbisko Therapeutics. It has obtained the Breakthrough Therapy Designation (BTD) from China NMPA and the U.S. FDA, as well as the PRIME designation from EMA. Furthermore, the U.S. FDA granted Fast Track Designation (FTD), and Orphan Drug Designation (ODD) granted by EMA, for the treatment of TGCT patients who are not amenable to surgery. Abbisko is conducting "a randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of pimicotinib (ABSK021) in patients with tenosynovial giant cell tumor (protocol No.: ABSK021-301)."

The release as fetched from its publisher. abbisko.com ↗